Blockchain Registration Transaction Record

STEMart Expands Biocompatibility Testing with Key Genotoxicity Assay

STEMart launches In Vivo Mouse Micronucleus Test for medical device genotoxicity assessment, ensuring compliance with ISO 10993-3 and OECD guidelines to enhance patient safety.

This news matters because it addresses a critical gap in medical device safety, directly impacting patient health and regulatory compliance. Genotoxicity testing, like the In Vivo Mouse Micronucleus Test, is essential for identifying substances that could cause chromosomal damage, potentially leading to cancer or other serious health issues. As medical devices become more advanced and widespread, rigorous testing ensures they do not introduce hidden risks. For manufacturers, this service streamlines the path to market approval under standards like ISO 10993-3, reducing development delays and liability. For consumers, it means safer healthcare products, fostering trust in medical innovations. In an era of rapid technological growth, such advancements in testing protocols are vital for balancing innovation with public safety, ultimately contributing to better health outcomes globally.